Abstract
Background
Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine that has numerous biological processes. Earlier research indicates that protein and mRNA production of TGF-β1 are enhanced in the renal tissues of patients with diabetic nephropathy (DN). Our aim was to evaluate the role of TGF-β1 in early prediction of DN in children with type 1 diabetes mellitus (T1DM).
Methods
Fifty patients with T1DM were enrolled in an observational study. Patients were eligible to participate if at least 3 years had passed since T1DM diagnosis. Patients were classified into two groups (A and B) according to the presence or absence of microalbuminuria, respectively. Serum TGF-β1 was measured by ELISA in the patients.
Results
Out of the 50 studied patients with T1DM, there were 23 (46%) patients with microalbuminuria. There was a significant difference between patients in group A and B as regards TGF-β1 (p < 0.001). HbA1c had very little influence in controlling for the relationship between TGF-β1 and disease duration. Diagnostic cutoff value of TGF-β1 was 358.5 pg/ml with sensitivity and specificity of 100%.
Conclusion
TGF-β1 was significantly higher in children with DN in comparison with children without. It could be used as an early indicator of DN in children with T1DM with high sensitivity and specificity.
Similar content being viewed by others
References
Chang AS, Hathaway CK, Smithies O, Kakoki M (2016) Transforming growth factor-beta1 and diabetic nephropathy. Am J Physiol Renal Physiol 310:F689–F696
Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak AG, Schloot NC, Witte DR (2009) Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 32:421–423
Fukuda N, Tahira Y, Matsuda H, Matsumoto K (2009) Transforming growth factor-beta as a treatment target in renal diseases. J Nephrol 22:708–715
Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576
Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171–3182
Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97:8015–8020
Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 15(Suppl 1):S55–S57
Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX, Zhao HL (2017) Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 96:e6583
Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN (1992) Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 41:107–114
Ziyadeh FN, Sharma K, Ericksen M, Wolf G (1994) Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93:536–542
Wolf G, Ziyadeh FN (2009) Transforming growth factor-b and diabetic nephropathy. J organ dysfunct 5:130–139
Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS (1997) Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46:854–859
Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424–S437
Chen S, Jim B, Ziyadeh FN (2003) Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 23:532–543
Hellmich B, Schellner M, Schatz H, Pfeiffer A (2000) Activation of transforming growth factor-beta1 in diabetic kidney disease. Metabolism 49:353–359
Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S (1993) Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Investig 68:154–163
Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA (1996) Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49:461–469
Hathaway CK, Gasim AM, Grant R, Chang AS, Kim HS, Madden VJ, Bagnell CR Jr, Jennette JC, Smithies O, Kakoki M (2015) Low TGFbeta1 expression prevents and high expression exacerbates diabetic nephropathy in mice. Proc Natl Acad Sci U S A 112:5815–5820
Lee EY, Chung CH, Khoury CC, Yeo TK, Pyagay PE, Wang A, Chen S (2009) The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 297:F85–F94
Sato H, Iwano M, Akai Y, Kurioka H, Kubo A, Yamaguchi T, Hirata E, Kanauchi M, Dohi K (1998) Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 18:490–494
Korpinen E, Teppo AM, Hukkanen L, Akerblom HK, Gronhagen-Riska C, Vaarala O (2000) Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care 23:664–668
Flores L, Naf S, Hernaez R, Conget I, Gomis R, Esmatjes E (2004) Transforming growth factor beta at clinical onset of type 1 diabetes mellitus. A pilot study. Diabet Med 21:818–822
Zorena K, Raczynska D, Wisniewski P, Malinowska E, Mysliwiec M, Raczynska K, Rachon D (2013) Relationship between serum transforming growth factor beta 1 concentrations and the duration of type 1 diabetes mellitus in children and adolescents. Mediat Inflamm 2013:849457
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee.
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights and informed consent
An informed consent was obtained from patients’ caregivers. The research does not include animals and there were no clinical trials on human subjects.
Rights and permissions
About this article
Cite this article
Sawires, H., Botrous, O., Aboulmagd, A. et al. Transforming growth factor-β1 in children with diabetic nephropathy. Pediatr Nephrol 34, 81–85 (2019). https://doi.org/10.1007/s00467-018-4062-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-018-4062-8